Amgen drug combined with immunotherapy extends survival in lung cancer trial
Amgen's Imdelltra combined with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The phase 3 trial, DeLLphi-305, showed that the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ IMDELLTRA in combination with IMFINZI reduced risk of death by an unprecedented 58% in first-line extensive stage small cell lung cancer.
- ✓ The combination extended median overall survival to 21.1 months compared to 12.7 months with IMFINZI alone.
- ✓ Nearly 80% of patients were alive at one year versus 53% with IMFINZI alone.
What changed
Amgen announced positive results from the DeLLphi-305 phase 3 trial, demonstrating a significant survival benefit with the combination of Imdelltra and Imfinzi.
Live updates
-
Amgen drug combo cuts lung cancer death risk by 58%
Amgen's Imdelltra combined with AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The phase 3 trial, DeLLphi-305, showed that the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.
Why it matters
Small cell lung cancer is an aggressive and hard-to-treat disease. Current treatments have limited efficacy, making new therapies crucial. The combination of Imdelltra and Imfinzi offers a significant survival benefit, potentially changing the treatment landscape. This development is particularly important for patients with extensive-stage small cell lung cancer.
What is confirmed
- IMDELLTRA in combination with IMFINZI reduced risk of death by an unprecedented 58% in first-line extensive stage small cell lung cancer.
- The combination extended median overall survival to 21.1 months compared to 12.7 months with IMFINZI alone.
- Nearly 80% of patients were alive at one year versus 53% with IMFINZI alone.
What to watch next
- Amgen's third quarter 2026 financial results announcement on November 3, 2026
- Further data presentations and publications on the DeLLphi-305 trial
- Regulatory decisions on the approval of Imdelltra in combination with Imfinzi
confidence 95%Sources used for this update (15)
- www.cnbc.com — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- CNBC — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Amgen — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- NBC News — ‘Practice-changing’ new lung cancer immunotherapy improves survival
- Fierce Pharma — ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer
- Reuters — Amgen drug combined with immunotherapy extends survival in lung cancer trial
- Bloomberg.com — Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
- www.marketscreener.com — Amgen drug combined with immunotherapy extends survival in lung cancer trial | MarketScreener
- arynews.tv — Amgen drug combined with immunotherapy extends survival in lung cancer trial - ARY News
- www.yahoo.com — Amgen drug combined with immunotherapy extends survival in ...
- www.amgen.com — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH ...
- pharma.economictimes.indiatimes.com — Amgen drug combined with immunotherapy extends survival in ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community